Loading
Neurotransmitter Receptor Influence on Behavior · Journal article
Middle East Current Psychiatry · August 17, 2026
Encouraging direction, but not yet definitive.
This prospective longitudinal study documents significant improvements in depression, anxiety, suicidal ideation, and most cognitive domains (attention, naming, executive function, memory, language, abstract reasoning) over 6 months of methamphetamine abstinence in a small Egyptian sample. While the repeated-measures design and consistent direction of improvement are encouraging, the small sample, lack of a control group, and single-centre setting limit the strength of evidence and generalizability of these findings.
Prospective longitudinal cohort study with repeated measures. 30 current or recent methamphetamine (Shabu) users at baseline, enrolled from both inpatient and outpatient treatment settings at the Neurology & Psychiatry Department and Psychiatry, Neurology and Neurosurgery Centre in Tanta University Hospitals.. Intervention: 6 months of methamphetamine abstinence (treatment setting unclear; appears to be standard clinical treatment). n = 30. Tanta University Hospitals, Tanta, Egypt.
Depression, anxiety, and suicidality were significantly lower at 3 months (T1) and 6 months (T2) compared to baseline (T0), with further significant reduction from T1 to T2 (P < 0.05) Attention, naming, and visual space/executive function subscale scores and total MoCA score were significantly higher at T1 and T2 versus T0, with further improvement at T2 versus T1 (P < 0.05) Language and memory/delayed recall subscale scores were significantly higher at T1 and T2 versus T0 (P < 0.05), with no significant difference between T1 and T2
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The findings suggest that methamphetamine abstinence is associated with clinically meaningful recovery of mood, anxiety, suicidal ideation, and cognitive function over 6 months, which could inform patient counselling and expectation-setting during addiction treatment. However, the small sample and lack of control group mean these results should be interpreted as preliminary evidence requiring confirmation in larger, controlled studies.
A prospective longitudinal study with repeated measures showing significant improvements in depression, anxiety, suicidality and most cognitive domains during 6 months of abstinence, but limited by small sample size and single-centre setting.
As stated by the source record.
Quoted from the source exactly as published.
The findings suggest that methamphetamine abstinence is associated with clinically meaningful recovery of mood, anxiety, suicidal ideation, and cognitive function over 6 months, which could inform patient counselling and expectation-setting during addiction treatment. However, the small sample and lack of control group mean these results should be interpreted as preliminary evidence requiring confirmation in larger, controlled studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background and objectives Methamphetamine use is increasing globally not only in developed countries but also in developing countries, including Egypt. The adverse impact of methamphetamine use (locally known as Shabu drug in Egypt) on psychiatric condition and cognitive functions has been described in previous studies, but limited evidence is available for abstinent users from prospective longitudinal studies especially in Egypt. The aim of this study was to assess the longitudinal changes in cognitive functions, anxiety, depression, and suicidality among methamphetamine users over 6 months of abstinence. Methods This prospective longitudinal study was conducted with baseline and two follow-up interviews every 3 months over 6 months of abstinence in 30 participants who were current or recent methamphetamine (shabu) users at baseline, in both the Inpatient and Outpatient Treatment Setting of the Neurology & Psychiatry Department, and Psychiatry, Neurology and Neurosurgery Centre in Tanta University Hospitals from July 2025 to December 2025. All patients underwent the assessment of socioeconomic data, assessment of patient’s level of depression by Beck depression inventory–II (BDI-II), the level of anxiety by generalized anxiety disorder-7 scale (GAD-7), the suicidal behaviour by Beck scale for suicidal ideation (BSSI) and assessment of cognitive functions by Montreal cognitive assessment (MoCA) test. Results The depression, anxiety and suicidality (assessed by previous measures) were significantly lower at T1 (after 3 months of abstinence) and T2 (after 6 months of abstinence) than T0 (baseline with recent methamphetamine use) ( P < 0.05) and were significantly lower at T2 than T1 ( P < 0.05). Regarding cognitive functions (assessed by Montreal cognitive assessment test, MoCA), the attention, naming, visual space/ executive function subscale scores and the total MoCA score were significantly higher at T1 and T2 than T0 ( P < 0.05) and was significantly higher at T2 than T1 ( P < 0.05). The language skills, and the memory and delayed recall subscale scores were significantly higher at T1 and T2 than T0 ( P < 0.05), with insignificant difference between T1 and T2. The abstract ability subscale score was significantly higher at T2 (6 months) than T0 (baseline) ( P < 0.05), with insignificant difference between T1 and T0. The orientation domain didn’t show statistical difference across three different time points of assessment. Conclusions Depression, anxiety, suicidal ideation and cognitive impairment were found to be high among current methamphetamine users, which showed significant improvement during 6 months of the methamphetamine abstinence.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.